Vaxil Historical Cash Flow
| VXL Stock | CAD 0.01 0.00 0.00% |
Analysis of Vaxil Bio cash flow over time is an excellent tool to project Vaxil Bio future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 19 K or Other Cashflows From Financing Activities of 2 K as it is a great indicator of Vaxil Bio ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Vaxil Bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vaxil Bio is a good buy for the upcoming year.
Vaxil |
About Vaxil Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Vaxil balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Vaxil's non-liquid assets can be easily converted into cash.
Vaxil Bio Cash Flow Chart
Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Capital Expenditures
Capital Expenditures are funds used by Vaxil Bio to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Vaxil Bio operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Vaxil Bio's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Vaxil Bio current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Vaxil Bio's Begin Period Cash Flow is fairly stable compared to the past year. Change To Operating Activities is likely to climb to about 198.2 K in 2024, whereas Stock Based Compensation is likely to drop slightly above 19 K in 2024.
| 2020 | 2021 | 2024 (projected) | Begin Period Cash Flow | 83K | 1.5M | 1.6M | End Period Cash Flow | 1.5M | 2.2M | 665.5K |
Vaxil Bio cash flow statement Correlations
Click cells to compare fundamentals
Vaxil Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Vaxil Bio cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (670K) | 1.4M | 731K | (731K) | (572K) | (543.4K) | |
| Stock Based Compensation | 142K | 150K | 70K | 17K | 20K | 19K | |
| Free Cash Flow | (596K) | (1.1M) | (1.1M) | (734K) | (561K) | (589.1K) | |
| Change In Working Capital | 307K | 37K | (193K) | (169K) | (327K) | (310.7K) | |
| Other Cashflows From Financing Activities | 3K | (68.0) | 1.9M | 1.8K | 2.1K | 2.0K | |
| Total Cash From Operating Activities | (596K) | (1.1M) | (1.1M) | (734K) | (561K) | (589.1K) | |
| Net Income | (1.2M) | (1.4M) | (986K) | (584K) | (254K) | (266.7K) | |
| Total Cash From Financing Activities | (68K) | 2.6M | 1.8M | 35K | 40.3K | 38.2K | |
| End Period Cash Flow | 753K | 83K | 1.5M | 2.2M | 938K | 665.5K | |
| Begin Period Cash Flow | 169K | 753K | 83K | 1.5M | 2.2M | 1.6M | |
| Other Non Cash Items | 9K | 11K | 38K | 10K | (320.0) | (304.0) | |
| Net Borrowings | (32K) | (68K) | (21K) | (9K) | (8.1K) | (7.7K) | |
| Depreciation | 56K | 100K | 57K | 25K | 2K | 0.0 | |
| Change To Account Receivables | 48K | (97K) | 82K | 11K | (7K) | (7.4K) | |
| Change To Operating Activities | 24K | 106K | (24K) | 164K | 147.6K | 198.2K | |
| Change To Netincome | 97K | 151K | 161K | 70K | 63K | 59.9K | |
| Change To Liabilities | 370K | (103K) | 283K | (30K) | (275K) | 0.0 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.